Literature DB >> 19894270

Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-beta-D-maltoside.

John J Arnold1, Michael D Fyrberg, Elias Meezan, Dennis J Pillion.   

Abstract

Regular insulin, NPH insulin, glargine insulin, calcitonin, and human growth hormone were administered to rats nasally with 0.125% tetradecyl-beta-D-maltoside (TDM), or at various times after TDM treatment. Absorption of all five peptides was enhanced initially and diminished in a time-dependent manner as the interval between administration of TDM and the peptide increased. Changes in nasal morphology were also assessed via transmission electron microscopy (TEM) immediately after TDM treatment and at various times thereafter. TEM analysis demonstrated that 0.125% TDM caused a rapid and transient alteration in the morphology of the apical membrane surface. Fewer cilia were observed and cell-cell junctions were difficult to visualize, but no epithelial cell erosion was apparent. Two hours after TDM treatment, the apical membrane surface once again contained abundant cilia and cell-cell junctions were readily visualized. The complete recovery of the nasal permeability barrier to several different peptides following TDM administration and the concomitant histological evidence demonstrate that TDM treatment transiently perturbs the nasal mucosa to stimulate peptide drug absorption and does not produce irreversible damage to the cells that line the nasal cavity. 2009 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19894270     DOI: 10.1002/jps.21977

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Absorption enhancers: applications and advances.

Authors:  Bruce J Aungst
Journal:  AAPS J       Date:  2011-11-22       Impact factor: 4.009

2.  High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers.

Authors:  Edward T Maggio; Dennis J Pillion
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

3.  CriticalSorb™: enabling systemic delivery of macromolecules via the nasal route.

Authors:  Andrew L Lewis; Faron Jordan; Lisbeth Illum
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

4.  CriticalSorb™ promotes permeation of flux markers across isolated rat intestinal mucosae and Caco-2 monolayers.

Authors:  D J Brayden; V A Bzik; A L Lewis; L Illum
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

Review 5.  Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art.

Authors:  Suzanne M de la Monte
Journal:  Expert Opin Drug Deliv       Date:  2013-11-12       Impact factor: 6.648

6.  Nasal absorption of mixtures of fast-acting and long-acting insulins.

Authors:  Dennis J Pillion; Michael D Fyrberg; Elias Meezan
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.